title: Long-term gefitinib treatment of occult lung carcinoma with multiple brain metastases.
authors.forename: Takehiko
authors.initials: T
authors.lastname: Kobayashi
authors.forename: Masayuki
authors.initials: M
authors.lastname: Takeda
authors.forename: Satoshi
authors.initials: S
authors.lastname: Marumo
authors.forename: Yoshihiko
authors.initials: Y
authors.lastname: Koshimo
authors.forename: Takashi
authors.initials: T
authors.lastname: Teranishi
authors.forename: Yuichi
authors.initials: Y
authors.lastname: Higami
authors.forename: Motokazu
authors.initials: M
authors.lastname: Kato
mesh_terms: D001932:Brain Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000556:secondary; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D066246:ErbB Receptors / Q000037:antagonists & inhibitors / Q000235:genetics; D005260:Female; D000077156:Gefitinib; D006801:Humans; D007150:Immunohistochemistry; D053552:Keratin-7 / Q000378:metabolism; D008168:Lung / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D008875:Middle Aged; D009154:Mutation; D009687:Nuclear Proteins / Q000378:metabolism; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use; D011799:Quinazolines / Q000627:therapeutic use*; D000074482:Thyroid Nuclear Factor 1; D013997:Time Factors; D014157:Transcription Factors / Q000378:metabolism; D016896:Treatment Outcome
chemical_list: D053552:Keratin-7; D009687:Nuclear Proteins; D047428:Protein Kinase Inhibitors; D011799:Quinazolines; D000074482:Thyroid Nuclear Factor 1; D014157:Transcription Factors; C512478:EGFR protein, human; D066246:ErbB Receptors; D000077156:Gefitinib